These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 34503646)

  • 21. Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1®) after nivolumab discontinuation.
    Komatsu-Fujii T; Ogawa M; Nonoyama S; Fukumoto T; Tanabe H
    Eur J Dermatol; 2021 Feb; 31(1):98-99. PubMed ID: 33586655
    [No Abstract]   [Full Text] [Related]  

  • 22. Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature.
    Seah J; Lin K; Tai D; Lim ST; Chan A
    Onkologie; 2012; 35(10):596-8. PubMed ID: 23038232
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
    Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
    Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).
    Chollet P; Schöffski P; Weigang-Köhler K; Schellens JH; Cure H; Pavlidis N; Grünwald V; De Boer R; Wanders J; Fumoleau P;
    Eur J Cancer; 2003 Jun; 39(9):1264-70. PubMed ID: 12763215
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increase in triglyceride blood level in patients treated with capecitabine: a retrospective survey.
    Bar-Sela G; Cohensius-Kent D; Vornikova O; Haim N
    Anticancer Drugs; 2014 Jul; 25(6):729-34. PubMed ID: 24595094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
    Saek T; Takashima S; Sano M; Horikoshi N; Miura S; Shimizu S; Morimoto K; Kimura M; Aoyama H; Ota J; Noguchi S; Taguchi T
    Breast Cancer; 2004; 11(2):194-202. PubMed ID: 15550867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pharmacokinetics of S-1 capsule in patients with advanced gastric cancer].
    Liu HY; Ding L; Yu Y; Chu Y; Zhu H
    Yao Xue Xue Bao; 2012 Oct; 47(10):1363-9. PubMed ID: 23289150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Rare Case of Reversible Cardiac Dysfunction Associated with Tegafur/Gimeracil/Oteracil (S-1) Therapy.
    Oyakawa T; Hua Z; Ebihara A; Shiga T
    Int Heart J; 2021 May; 62(3):700-705. PubMed ID: 33994512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe Hypertriglyceridemia Induced by Sirolimus Treated With Medical Management Without Plasmapheresis: A Case Report.
    Kido K; Evans RA; Gopinath A; Flynn JD
    J Pharm Pract; 2018 Feb; 31(1):104-106. PubMed ID: 28205445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.
    Najib J
    Clin Ther; 2002 Dec; 24(12):2022-50. PubMed ID: 12581543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients.
    Sakata Y; Ohtsu A; Horikoshi N; Sugimachi K; Mitachi Y; Taguchi T
    Eur J Cancer; 1998 Oct; 34(11):1715-20. PubMed ID: 9893658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
    Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
    Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
    Bar-Sela G; Haim N
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling.
    Kim TH; Shin S; Shin JC; Bulitta JB; Weon KY; Yoo SD; Park GY; Jeong SW; Kwon DR; Min BS; Woo MH; Shin BS
    Molecules; 2017 Sep; 22(9):. PubMed ID: 28880240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Capecitabine-induced hypertriglyceridemia: a report of two cases.
    Koutras AK; Habeos IG; Vagenakis AG; Kalofonos HP
    Anticancer Res; 2006; 26(3B):2249-51. PubMed ID: 16821596
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
    Komatsu Y; Yuki S; Fuse N; Kato T; Miyagishima T; Kudo M; Kunieda Y; Tateyama M; Wakahama O; Meguro T; Sakata Y; Asaka M
    Adv Ther; 2010 Jul; 27(7):483-92. PubMed ID: 20559897
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tegafur/gimeracil/oteracil (TS-1)-induced erythroderma with an extensive mucosal involvement and hand-foot syndrome.
    Matsuda K; Namiki T; Ueno M; Hashimoto T; Hanafusa T; Yokozeki H
    Eur J Dermatol; 2017 Jun; 27(3):323-325. PubMed ID: 28414195
    [No Abstract]   [Full Text] [Related]  

  • 38. [Provision for adverse effect of S-1 containing chemotherapy in patients with advanced digestive cancer--combination with superfine dispersed lentinan].
    Yagi M; Watanabe S; Yoshino S; Hazama S; Suga T; Nakazawa S
    Gan To Kagaku Ryoho; 2010 Mar; 37(3):457-62. PubMed ID: 20332683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypertriglyceridemia in patients with psoriasis treated with cyclosporine.
    Grossman RM; Delaney RJ; Brinton EA; Carter DM; Gottlieb AB
    J Am Acad Dermatol; 1991 Oct; 25(4):648-51. PubMed ID: 1791223
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors.
    Hoff PM; Saad ED; Ajani JA; Lassere Y; Wenske C; Medgyesy D; Dwivedy S; Russo M; Pazdur R
    Clin Cancer Res; 2003 Jan; 9(1):134-42. PubMed ID: 12538461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.